Gilteritinib for the Treatment of ALK NSCLC

Clinical trial NCT06225427 · RECRUITING

Trial details

NCT number: NCT06225427
Sponsor: University of Michigan Rogel Cancer Center
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Lung Non-Small Cell Carcinoma Stage IV Lung Cancer AJCC v8

Start date: 2024-07-25
Primary completion: 2027-05-01
Enrollment: 30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.